Professional
Added to YB: 2024-03-11
Pitch date: 2024-03-07
JAZZ [bullish]
Jazz Pharmaceuticals plc
+60.58%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.
Market Cap
$11.2B
Pitch Price
$116.36
Price Target
187.00 (+0%)
Dividend
N/A
EV/EBITDA
8.27
P/E
-31.16
EV/Sales
3.33
Sector
Pharmaceuticals
Category
value
Show full summary:
Jazz Pharmaceuticals plc: Xywav, Rylaze, and Epidiolex Drive Growth; Shares Undervalued
JAZZ: Xywav, Rylaze, Epidiolex fuel 27% YoY rise; generic Xyrem pressure but Xywav shift & Lumryz compete. $187 FVE on $4.1B '24 rev. No moat from patents; GW buy costly yet strategic w/ $865M '23 rev. High uncertainty, heavy on acquisitions & debt, pivotal commercial prowess.
Read full article (11 min)